SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)

Inclusion Criteria

• •For participants with AML:
• •* Age \>=60 years, either sex, any race.
• •* Diagnosis of CD33-positive AML by World Health Organization criteria.
• •* Must be in first or second relapse, or have primary refractory or refractory disease at first salvage, and not be considered a candidate for transplant.
• •* Acute promyelocytic leukemia who has relapsed following treatment with both all trans retinoic acid (tretinoin) and arsenic trioxide-based therapy is eligible.
• •For participants with ALL:
• •* Age \>=18 years, either sex, any race.
• •* Diagnosis of ALL by World Health Organization criteria.
• •* Must be in first or second relapse, or have primary refractory or refractory disease at first salvage, and not be considered a candidate for potentially curative therapy.
• •* Eastern Cooperative Oncology group performance status of 0 or 1.
• •* Adequate hematologic, renal, and hepatic organ function and laboratory parameters.
• •* Receiving treatment with hydroxyurea or leukapheresis to reduce elevated white blood cell count to \<=30 x 10\^9 is eligible, provided hydroxyurea and leukapheresis are discontinued at least 24 hours before initiation of study drug.